Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), M3 (OtherMTHRF) and Sarepta Therapeutics (SRPT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report), M3 (MTHRF – Research Report) and Sarepta Therapeutics (SRPT – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vir Biotechnology (VIR)
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Vir Biotechnology, with a price target of $14.00. The company’s shares closed last Friday at $7.19, close to its 52-week low of $6.40.
According to TipRanks.com, Stringer is a 5-star analyst with an average return of
Currently, the analyst consensus on Vir Biotechnology is a Strong Buy with an average price target of $16.33, implying a 131.3% upside from current levels. In a report issued on January 30, TipRanks – Google also upgraded the stock to Buy with a $8.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
M3 (MTHRF)
In a report released today, Hidemaru Yamaguchi from Citi maintained a Buy rating on M3, with a price target of Yen2800.00. The company’s shares closed last Friday at $11.42.
According to TipRanks.com, Yamaguchi is a 1-star analyst with an average return of
M3 has an analyst consensus of Moderate Buy, with a price target consensus of $17.37, representing a 52.1% upside. In a report issued on February 6, Nomura also maintained a Buy rating on the stock with a Yen3720.00 price target.
Sarepta Therapeutics (SRPT)
In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Sarepta Therapeutics, with a price target of $20.00. The company’s shares closed last Friday at $18.50.
According to TipRanks.com, Ulz is a 2-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $22.47 average price target, which is a 27.7% upside from current levels. In a report issued on January 26, RBC Capital also maintained a Hold rating on the stock with a $18.00 price target.
